ARI-3037MO: Phase I data
Data from a pair of placebo-controlled Phase I trials in 58 healthy volunteers total showed that single and multiple ascending-doses of once-daily ARI-3037MO for 14 days were well tolerated with no treatment-related adverse events reported....
